One of the reasons research into medical cannabis has leapt so high in recent years is that the plant itself is remarkably complex. There are 142 different “cannabinoids” – active components – in cannabis that can target different illnesses.
The two best known are THC, the main psychoactive ingredient that also treats pain and nausea; and CBD, which is non-hallucinogenic and works on the autoimmune system.
The cannabis plant also contains terpenes, fragrant oils that provide a distinctive flavor and aroma. Many cannabis blends are named after their terpenes, which can provide a “blueberry” or “sour diesel” taste, for instance.
Israeli medical cannabis company Bazelet announced this week that it has developed proprietary technology to isolate and utilize specific terpenes to treat specific ailments, including chronic pain, post-traumatic stress disorder (PTSD), neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases, epilepsy and autism.
Bazelet says its technology can “improve the therapeutic quality of cannabis by adding a small amount of selected and indication-specific terpene blends.”
Bazelet has been conducting clinical trials on terpenes for pain relief and PTSD at Hadassah University Medical Center in Jerusalem and for epilepsy at Schneider Children’s Medical Center of Israel in Petah Tikva.
Bazelet last year filed its first patent application for the terpene technology and two more are planned. The company has filed 14 patent applications in total for medical cannabis-based products including packaged cannabis buds, cannabis oil, sustained release cannabis capsules, and the PUFFiT-X vaporizer that looks and works like an asthma inhaler.
Bazelet is also closely tracking proposed changes in Israeli law that may soon enable massively increased exports of medical cannabis. The company is ready with a new manufacturing site that will have an extraction capacity of 60 tons of year, sufficient to serve 100,000 medical cannabis patients.
Bazelet runs a technology incubator out of which 10 patent applications have been filed in the last year alone. That could be a profitable IP portfolio to have: The medical cannabis market is expected to reach a market value of $56 billion by 2025.